Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, S-INFINITY Pharmaceuticals, has received approval from the National Medical Products Administration to commence a Phase II clinical trial for XH-S003 capsules, a small molecule inhibitor targeting paroxysmal nocturnal hemoglobinuria (PNH). This development marks a significant step in the company’s efforts to address rare blood disorders, potentially enhancing its market position and offering new treatment options for patients with complement-mediated diseases.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical products. The company is known for its innovative approach in drug development, particularly in the area of chemical medicines, and has a significant market presence in China.
YTD Price Performance: 7.95%
Average Trading Volume: 5,322
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.38B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.